Clinical development of Sulforadex®: an Antioxidant Inflammation Modulator (AIM) with application in oncology, inflammation and neuroprotection
Antioxidant Inflammation Modulators (AIMs) activate the transcription factor Nrf2 and offer a promising therapeutic approach for diseases driven by oxidative stress, including many cancers, inflammatory and neurodegenerative diseases. The first AIM to gain regulatory approval is Biogen's BG-12, recently approved for relapsing remitting multiple sclerosis and on track to blockbuster status.
Evgen Pharma is a clinical stage company focused on developing novel drugs based upon sulforaphane. The Company's lead product is Sulforadex®. Sulforadex® is a novel AIM that has completed two Phase I clinical trials, demonstrating excellent bioavailability, safety and tolerance. The product has potential broad utility in oncology and neurology.